Isolation and Phenotypic Characterisation of Stem Cells from Late Stage Osteoarthritic Mesenchymal Tissues

Lăbuşcă, Luminiţa; Zugun‐Eloae, Florin; Shaw, Georgina; Botez, Paul; Barry, Frank; Mashayekhi, Kaveh

doi:10.2174/157488812802481490

Cited by 3 publications

(3 citation statements)

References 34 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the stem cells typically used in these studies are from young, healthy donors and may not reflect the expansion and differentiation characteristics of stem cells from OA patients requiring autologous stem cell therapy. Given previous indications that the presence of OA may reduce the chondrogenic capacity of stem cells [3], it was important that several recent studies have confirmed that MSCs from OA patients are able to be isolated, expanded, and differentiated toward the chondrocyte lineage [4, 5]. However, patient characteristics other than OA itself may serve as important selection criteria for stem cell-based repair strategies.…”

Section: The Effects Of Age and Disease On Stem Cell Propertiesmentioning

confidence: 99%

Stem cell-based therapies for osteoarthritis

Diekman

Guilak

2013

Current Opinion in Rheumatology

128

137

View full text Add to dashboard Cite

Purpose of review Regenerative medicine offers the exciting potential of developing alternatives to total joint replacement for treating osteoarthritis (OA). In this article, we highlight recent work that addresses key challenges of stem cell-based therapies for OA and provide examples of innovative ways in which stem cells can aid in the treatment of OA. Recent findings Significant progress has been made in understanding the challenges to successful stem cell therapy, such as the effects of age or disease on stem cell properties, altered stem cell function due to an inflammatory joint environment, and phenotypic instability in vivo. Novel scaffold designs have been shown to enhance the mechanical properties of tissue-engineered cartilage and have also improved the integration of newly formed tissue within the joint. Emerging strategies such as injecting stem cells directly into the joint, manipulating endogenous stem cells to enhance regenerative capacity, and utilizing stem cells for drug discovery have expanded the potential uses of stem cells in treating OA. Summary A number of recent studies have greatly advanced the development and pre-clinical evaluation of potential stem cell-based treatments for OA through novel approaches focused on cell therapy, tissue engineering, and drug discovery.

show abstract

Section: The Effects Of Age and Disease On Stem Cell Propertiesmentioning

confidence: 99%

Stem cell-based therapies for osteoarthritis

Diekman

Guilak

2013

Current Opinion in Rheumatology

128

137

View full text Add to dashboard Cite

show abstract

“…Further complicating the consensus data in the application of hASC for musculoskeletal tissue engineering, investigators have reported that mesenchymal and adipose-derived stem cells isolated from patients or animal models of osteoarthritis have full capacity to differentiate into osteogenic, chrondrogenic, and adipogenic tissues. 18,19 Additionally, there is evidence that rabbit ASC derived from osteoporotic rabbits have a comparable capacity for in vitro osteogenic differentiation as compared with healthy rabbits, suggesting that a disease such as osteoporosis does not preclude the use of ASC in autologous therapies. 20 However, what a majority of investigators do agree upon is that high donor-to-donor variability is a barrier to understanding the consensus behaviors of hASC differentiation and, moreover, a barrier to their widespread clinical use.…”

Section: Introductionmentioning

confidence: 99%

Age-Related Effects on the Potency of Human Adipose-Derived Stem Cells: Creation and Evaluation of Superlots and Implications for Musculoskeletal Tissue Engineering Applications

Bodle

Teeter

et al. 2014

Tissue Engineering Part C: Methods

View full text Add to dashboard Cite

Human adipose-derived stem cells (hASC) are now a prevalent source of adult stem cells for studies in tissue engineering and regenerative medicine. However, researchers utilizing hASC in their investigations often encounter high levels of donor-to-donor variability in hASC differentiation potential. Because of this, conducting studies with this primary cell type can require extensive resources to generate statistically significant data. We present a method to generate pooled donor cell populations, termed ''superlots,'' containing cell populations derived from four to five age-clustered donors. The goal of generating these superlots was to 1) increase experimental throughput, 2) to utilize assay resources more efficiently, and 3) to begin to establish global hASC differentiation behaviors that may be associated with donor age. With our superlot approach, we have validated that pooled donor cell populations exhibit proliferative activity representing the combined behavior of each individual donor cell line. Further, the superlots also exhibit differentiation levels roughly approximating the average combined differentiation levels of each individual donor cell line. We established that high donor-to-donor variability exists between the pre-, peri-, and postmenopausal age groupings and that proliferation and differentiation characteristics can vary widely, independent of age. Interestingly, we did observe that cell lines derived from postmenopausal donors demonstrated a relatively high proclivity for osteogenic differentiation and a relatively lowered proclivity for adipogenic differentiation as compared with cells derived from pre-and perimenopausal donors. In general, superlots effectively represented the average differentiation behavior of each of their contributing cell populations and could provide a powerful tool for increasing experimental throughput to more efficiently utilize resources when studying hASC differentiation.

show abstract

“…However, there were some reports suggesting that sufficient numbers of MSCs can be collected from the old age patients, patients with end-stage arthritis, proximal femur, and distal femur. Further, the differentiation potential in the abovementioned cases has been confirmed [ 14 , 29 , 35 ]. In addition, mononuclear stem cells from young-aged healthy donors have been reported to differ between donors in their differentiation potentials [ 30 ].…”

Section: Discussionmentioning

confidence: 89%

Clinical efficiency of bone marrow mesenchymal stem cell implantation for osteonecrosis of the femoral head: a matched pair control study with simple core decompression

et al. 2018

View full text Add to dashboard Cite

BackgroundTo date, several trials have reported the use of mesenchymal stem cell (MSC) implantation for osteonecrosis of the femoral head (ONFH). However, the clinical outcomes have not been conclusive. This study compared the clinical and radiological results of bone marrow mesenchymal stem cell (BMMSC) implantation with traditional simple core decompression (CD) using a matched pair case–control design.MethodsWe retrospectively reviewed 100 patients with ONFH (106 hips) who had been treated by CD alone (50 patients, 53 hips) and CD + BMMSC implantation (50 patients, 53 hips) between February 2004 and October 2014. We assessed the total hip replacement arthroplasty (THA) conversion rate and ARCO (Association Research Circulation Osseous) stage progression. Survivor rate analysis was performed using the Kaplan–Meier method, and an additional THA was defined as the primary endpoints.ResultsThe mean follow-up period was 4.28 years. There was a difference in the THA conversion rate between the CD (49%) and CD + BMMSC groups (28.3%) (p = 0.028). ARCO stage progression was noted in 20 of 53 hips (37.7%) in the CD group and 19 of 53 hips (35.8%) in the CD + BMMSC group. Among collapsed cases (ARCO stages III and IV), there was no difference in clinical failure rate between the two groups. Conversely, in the pre-collapse cases (ARCO stages I and II), only 6 of 30 hips (20%) progressed to clinical failure in the CD + BMMSC group, whereas 15 of 30 hips (50%) progressed to clinical failure in the CD group (p = 0.014). Kaplan–Meier survival analysis showed a significant difference in the time to failure between the two groups up to 10-year follow-up (log-rank test p = 0.031). There was no significant difference in terms of age (p = 0.87) and gender (p = 0.51) when comparing THA conversion rates between groups. No complication was noted.ConclusionsThese results suggest that implantation of MSCs into the femoral head at an early stage of ONFH lowers the THA conversion rate. However, ARCO stage progression is not affected by this treatment.Trial registrationRetrospectively registered

show abstract

Isolation and Phenotypic Characterisation of Stem Cells from Late Stage Osteoarthritic Mesenchymal Tissues

Cited by 3 publications

References 34 publications

Stem cell-based therapies for osteoarthritis

Stem cell-based therapies for osteoarthritis

Age-Related Effects on the Potency of Human Adipose-Derived Stem Cells: Creation and Evaluation of Superlots and Implications for Musculoskeletal Tissue Engineering Applications

Clinical efficiency of bone marrow mesenchymal stem cell implantation for osteonecrosis of the femoral head: a matched pair control study with simple core decompression

Contact Info

Product

Resources

About